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MaBACKGROUND Little is known about mode of death after acute heart failure (AHF) hospitalization. In the RELAX-AHF
(Efﬁcacy and Safety of Relaxin for the Treatment of Acute Heart Failure) study, serelaxin, the recombinant form of
human relaxin-2, reduced post-discharge mortality at 180 days in selected patients with AHF.
OBJECTIVES The goal of this study was to assess the effect of serelaxin on speciﬁc modes of death in patients with AHF.
METHODS The RELAX-AHF study randomized 1,161 patients with AHF to 48 h of therapy with intravenous serelaxin or
placebo. Patients were followed for vital status through 180 days. A blinded clinical events committee reviewed all
deaths and adjudicated a cause of death on the basis of pre-speciﬁed criteria. Cox proportional hazard models were used
to assess the effect of serelaxin on each mode of death, on the basis of pre-speciﬁed groupings of mode of death.
RESULTS There were 107 deaths (9.3%): 37 (35%) due to HF, 25 (23%) due to sudden death, 15 (14%) due to other
cardiovascular (CV) causes, 19 (18%) due to non-CV causes, and 11 (10%) classiﬁed as unknown. The treatment effect
of serelaxin was most pronounced on other CV deaths (hazard ratio [HR]: 0.29; 95% CI: 0.12 to 0.73; p ¼ 0.005) and
sudden death (HR: 0.46; 95% CI: 0.20 to 1.07; p ¼ 0.065). There was no apparent impact of serelaxin treatment on
HF deaths or non-CV deaths.
CONCLUSIONS In the RELAX-AHF study, the effects of serelaxin on mortality were primarily driven by reduction in
mortality from other CV causes and sudden death, without apparent impact on HF deaths. (Efﬁcacy and Safety of Relaxin
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ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome(s)
AHF = acute heart failure
AMI = acute myocardial
infarction
CV = cardiovascular
HF = heart failure
ICD = implantable
cardioverter-deﬁbrillator
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1592H eart failure (HF) is among theleading causes of mortality andmorbidity worldwide (1,2). Hos-
pitalization for acute HF (AHF) is associated
with high post-discharge mortality, typically
10% to 20% by 6 months (3–5). The most com-
mon modes of death in patients with HF are
death from progressive HF and sudden car-
diac death (6,7). Despite the well-recognized
mortality risk after AHF hospitalization, rela-
tively little is known about the mode of death
in these patients, although HF and suddenHFcardiac death appear to predominate (8). Understand-
ing the treatment effects of speciﬁc therapies on mode
of death can provide insight into the mechanism of ac-
tion of the therapy as well as the pathophysiology of
HF generally. Additionally, the time course of various
types of post-discharge events may have implications
for the frequency and intensity of clinical follow-up.Su
De
De
SEE PAGE 1599In the RELAX-AHF (Efﬁcacy and Safety of Relaxin for
the Treatment of Acute Heart Failure) study, serelaxin,
the recombinant form of human relaxin 2, a naturally
occurring vasoactive peptide hormone with diverse
biological and hemodynamic effects, reduced post-
discharge mortality at 180 days in selected patients
with AHF treated within 16 h of initial presentation
(3). For insight into the possible mechanisms of action
of this treatment effect, we evaluated the effect
of serelaxin treatment on the mode of death in the
RELAX-AHF study, as well as the time course of
different modes of death during follow-up.
METHODS
The design and primary results of the RELAX-AHF
study (9) were published previously (3,10,11).
Brieﬂy, the RELAX-AHF study was a double-blind,
prospective, multicenter clinical trial that random-
ized 1,161 patients within 16 h of AHF presentation to
either intravenous serelaxin (30 mg/kg/day, n ¼ 581)
or matching placebo (n ¼ 580) for up to 48 h. To be
eligible for enrollment, patients had to have conges-
tion on chest radiograph, dyspnea at rest or with
minimal exertion, elevated natriuretic peptide levels,
systolic blood pressure >125 mm Hg, and mild to
moderate renal insufﬁciency. The primary endpoints
of the study were dyspnea assessment by change
in the visual analog scale from baseline to day 5 and
by Likert scale during the ﬁrst 24 h. All patients
were followed to 180 days for the pre-speciﬁed efﬁ-
cacy endpoint of cardiovascular (CV) mortality and
the safety endpoint of all-cause mortality.EVENT ADJUDICATION PROCESS. A clinical events
committee composed of 4 cardiologists (G.M.F., J.B.,
A.F.H., and A.B.M.) with expertise in HF and experi-
ence in adjudicating clinical events in trials of CV
disease who were blinded to treatment allocation
adjudicated all deaths through day 180. For each
event, the committee reviewed the case report form,
narrative summary provided by the study investigator,
and all available relevant source documents from
the medical record, including hospital notes, telem-
etry or implantable cardioverter-deﬁbrillator (ICD)
interrogations, discharge summaries, autopsy reports,
and death certiﬁcates. Deﬁnitions for each cause of
death were prospectively developed by the clinical
events committee and approved by the study execu-
tive committee before the start of the study. Speciﬁc
deﬁnitions used for adjudication were as follows:death: Deaths occurring in the context of
clinically worsening symptoms and/or signs of
HF without evidence of another cause of death
were classiﬁed as HF deaths. Hospitalized pa-
tients being actively treated for HF who had a
sudden death as the terminal event in the
hospital were classiﬁed with HF death.
dden cardiac death: Deaths that occurred un-
expectedly in a previously stable patient were
adjudicated as sudden cardiac deaths. An
unwitnessed death in a patient last seen alive
within 72 h who, at that time, did not manifest
another life-threatening disease or process was
classiﬁed as sudden cardiac death.
ath due to acute coronary syndrome (ACS):
Deaths occurring up to 14 days after a docu-
mented acute myocardial infarction (AMI) or by
autopsy ﬁndings showing recent MI or recent
coronary thrombus and when there was no
conclusive evidence of another cause of death
were classiﬁed as deaths due to ACS. Adjudi-
cation of MI required creatine kinase-MB >2 
the upper limit of the normal (ULN) or troponin
I or T >2  ULN and either typical clinical pre-
sentation consistent with MI or typical elec-
trocardiogram (ECG) changes consisting of new
abnormal Q waves in at least 2 consecutive
leads or evolving, ischemic ST-segment or
T-wave changes in at least 2 consecutive leads,
or new left bundle branch block. If death
occurred before biochemical conﬁrmation of
myocardial necrosis could be obtained, adju-
dication was on the basis of clinical presenta-
tion and ECG evidence.
ath due to stroke: Deaths occurring up to 30
days after a suspected or conﬁrmed stroke on
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1593the basis of clinical signs and symptoms as well
as neuroimaging and/or autopsy and when
there was no conclusive evidence of another
cause of death were adjudicated as deaths
due to stroke. This category included deaths
occurring up to 30 days after a stroke that were
either due to the stroke or caused by a
complication of the stroke.
er CV causes of death: Deaths due to another
documented CV cause or from complications
from a CV intervention were adjudicated as
such.
known/presumed CV death: Deaths not attrib-
utable to any apparent CV cause or non-CV
cause and for which there was no additional
relevant information were classiﬁed as un-
known deaths. For the purpose of the endpoint
of CV mortality, these events were presumed to
be CV in nature.
ath due to renal failure: Deaths were classiﬁed
as due to renal failure when the reason for
death was primarily due to documented signs,
symptoms, or laboratory abnormalities directly
related to renal dysfunction; no other acute
perturbation was responsible for the death;
and/or antemortem therapeutic interventions
included those directed toward treatment of
renal failure.
aths due to non-CV or nonrenal causes: Deaths
with a clearly identiﬁed non-CV or nonrenal
cause as deﬁned previously were adjudicated
into speciﬁc categories (e.g., malignancy, sepsis).Other CV
death
24%
Sudden
Death
23%
Heart 
Failure
Death
35%
FIGURE 1 Categories for Mode of Death
Categories for causes of death in the RELAX-AHF (Efﬁcacy and
Safety of Relaxin for the Treatment of Acute Heart Failure) study
are shown. Contiguous slices sum to the more general categories
of cardiovascular (CV) death and non-CV death. The subcategory
other CV death includes deaths due to acute coronary syndromes
or CV procedures and those classiﬁed as unknown/presumed CV.STATISTICAL ANALYSIS. Baseline characteristics were
described using appropriate descriptive statistics
(percentages, means and SDs, or medians and intra-
quartile ranges depending on the type of variable
and its distribution). Because some causes of death
were relatively infrequent, deaths were grouped into
4 predeﬁned categories for the purposes of this
analysis: HF death, sudden death, other CV death,
and non-CV death. Deaths classiﬁed as unknown/
presumed CV death were included with the other CV
deaths for the purposes of analysis. Because these
deaths generally occurred out of hospital, a sensi-
tivity analysis was performed with these deaths
reclassiﬁed as sudden deaths. Fourteen patients with
180-day vital status that was not known (they were
followed for less than the required 173 days) were
excluded from the comparisons of baseline charac-
teristics between survivors and those who died. Cox
proportional hazard models were used to assess the
treatment effect of serelaxin on each mode of death.All patients were included in these models with
follow-up time censored at the last date known alive
or date of death from another mode, and hazard ratios
(HRs) with associated 95% conﬁdence intervals (CIs)
estimated from these models are presented. The p
values from the log-rank test are presented. Because
event rates were low, an analysis taking competing
risks into account on the basis of methods of Fine and
Gray (12) resulted in nearly identical results. The
heterogeneity of serelaxin’s effect on the different
categories of modes of death was tested by con-
structing a 3-df chi-square test from estimates of the 4
log HRs and their covariance matrix obtained using
the Wei-Lin-Weissfeld method (13). SAS release 9.2
(SAS Institute, Inc., Cary, North Carolina) was used for
analyses.
RESULTS
Of the 1,161 patients enrolled in RELAX-AHF, there
were 14 with an unknown 180-day vital status. A total
of 107 patients (9.3%) died. Of the 107 deaths, 88
(82%) were CV and 19 (18%) were non-CV. Within the
category of CV death, 37 (35%) were due to HF, 25
(23%) were classiﬁed as sudden cardiac death, and 26
TABLE 1 Baseline Ch
Baseline Character
Age, yrs
Weight, kg
Systolic blood pressure
Diastolic blood pressur
Heart rate, beats/min
Respiratory rate, breat
Most recent ejection fr
No. of admissions for H
in past year
Men
White
Ejection fraction <40%
Admitted to hospital fo
HF in past year
Medical history
Hypertension
Hyperlipidemia
Stroke
Cigarette smoking
Peripheral vascular d
Mitral regurgitation
Ischemic heart diseas
Pacemaker
Biventricular pacing
ICD
Atrial ﬁbrillation or ﬂ
Chronic lung disease
Diabetes mellitus
eGFR, ml/min/1.73 m2
NT-proBNP, ng/l
Troponin T, mg/l
Values are mean  SD, n (
CV ¼ cardiovascular; eGF
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1594(24%) were classiﬁed as other CV death (Figure 1).
Baseline characteristics for survivors compared with
those for each of the 4 analysis categories are shown
in Table 1. Of the deaths classiﬁed as other CV death,
2 were due to ACS, 4 were due to stroke, 9 were
related to CV procedures, and 11 were adjudicated
as unknown/presumed CV. There were no deaths
due to renal failure. The deaths adjudicated into
each speciﬁc category for serelaxin and placebo are
shown in Table 2.
EFFECT OF SERELAXIN TREATMENT ON SPECIFIC
MODES OF DEATH. As reported previously, serelaxin
treatment was associated with a substantial decrease
in the rate of CV death (HR: 0.63; 95% CI: 0.41 to 0.96;
p ¼ 0.028) and all-cause death (HR: 0.63; 95% CI: 0.43
to 0.93; p ¼ 0.020) (3). The treatment effect of ser-
elaxin was most pronounced on other CV death (HR:
0.29; 95% CI: 0.12 to 0.73; p ¼ 0.005) and suddenaracteristics by Vital Status and Mode of Death
istics
Survivors
(n ¼ 1,040)
Nonsurvivors
(n ¼ 107)
HF Death
(n ¼ 37)
71.8  11.2 73.8  10.5 75.0  10.9
82.5  18.7 80.7  16.7 79.7  16.9
, mm Hg 142.7  16.6 137.9  15.9 140.1  16.3
e, mm Hg 82.2  13.7 79.5  13.5 78.1  13.0
79.3  14.6 82.3  16.9 82.4  14.8
hs/min 21.8  4.6 22.8  5.0 21.8  4.9
action, % 38.6  14.4 38.7  16.0 37.4  15.8
F 1.6  1.1 2.1  2.5 2.3  3.3
650 (62.5) 68 (63.6) 25 (67.6)
982 (94.4) 100 (93.5) 35 (94.6)
539 (54.9) 54 (54.0) 21 (60.0)
r 352 (33.8) 41 (38.3) 14 (37.8)
899 (86.4) 96 (89.7) 31 (83.8)
556 (53.5) 53 (49.5) 14 (37.8)
132 (12.7) 24 (22.4) 3 (8.1)
137 (13.2) 14 (13.1) 3 (8.1)
isease 127 (12.2) 27 (25.2) 10 (27.0)
318 (30.6) 38 (35.5) 16 (43.2)
e 540 (51.9) 59 (55.1) 23 (62.2)
103 (9.9) 15 (14.0) 9 (24.3)
95 (9.1) 16 (15.0) 6 (16.2)
134 (12.9) 18 (16.8) 7 (18.9)
utter 529 (50.9) 64 (59.8) 21 (56.8)
164 (15.8) 18 (16.8) 11 (29.7)
495 (47.6) 53 (49.5) 19 (51.4)
53.9  13.0 49.5  13.0 51.2  14.7
4,834 (4,575–5,108) 7,458 (6,380–8,717) 9,211 (7,065–12,01
0.034 (0.032–0.035) 0.055 (0.046–0.067) 0.063 (0.045–0.08
%), or geometric mean (95% CI).
R ¼ estimated glomerular ﬁltration rate; HF ¼ heart failure; ICD ¼ implantable cardiovertedeath (HR: 0.46; 95% CI: 0.20 to 1.07; p ¼ 0.065)
(Central Illustration). There was no apparent impact of
serelaxin treatment on HF deaths (HR: 1.16; 95% CI:
0.61 to 2.21; p ¼ 0.655) or non-CV deaths (HR: 0.71;
95% CI: 0.29 to 1.76; p ¼ 0.548). Kaplan-Meier curves
for each of the 4 primary categories of mode of death
are shown in Figure 2. In an alternate sensitivity
analysis, when unknown deaths were reclassiﬁed as
sudden death, results were generally similar,
although the HR for the effect of serelaxin on sudden
death reached statistical signiﬁcance (HR: 0.49; 95%
CI: 0.25 to 0.98; p ¼ 0.039).
Because the other CV death category included a
variety of causes of death, we assessed these indi-
vidually (Table 2). The most notable difference in
this category was regarding death from stroke, which
showed 1 death (0.2%) in the serelaxin group com-
pared with 8 deaths (1.5%) with placebo. Of theseSudden Death
(n ¼ 25)
Other CV Death
(n ¼ 26)
Non-CV Death
(n ¼ 19)
70.6  10.8 73.4  10.6 76.4  9.0
80.5  18.0 83.2  17.7 79.5  14.1
132.8  9.8 141.8  17.2 134.7  18.5
79.5  15.0 82.0  13.1 78.8  13.1
85.4  20.8 85.5  16.2 73.3  13.8
22.9  4.6 23.8  5.1 22.9  5.4
35.0  12.2 38.7  17.6 45.5  17.2
2.4  2.1 1.2  0.4 2.9  2.9
13 (52.0) 19 (73.1) 11 (57.9)
24 (96.0) 24 (92.3) 17 (89.5)
14 (63.6) 10 (41.7) 9 (47.4)
7 (28.0) 11 (42.3) 9 (47.4)
24 (96.0) 24 (92.3) 17 (89.5)
12 (48.0) 16 (61.5) 11 (57.9)
6 (24.0) 6 (23.1) 9 (47.4)
6 (24.0) 3 (11.5) 2 (10.5)
3 (12.0) 10 (38.5) 4 (21.1)
8 (32.0) 5 (19.2) 9 (47.4)
13 (52.0) 12 (46.2) 11 (57.9)
2 (8.0) 2 (7.7) 2 (10.5)
3 (12.0) 5 (19.2) 2 (10.5)
4 (16.0) 4 (15.4) 3 (15.8)
14 (56.0) 17 (65.4) 12 (63.2)
1 (4.0) 2 (7.7) 4 (21.1)
14 (56.0) 10 (38.5) 10 (52.6)
47.4  12.9 50.9  12.8 46.9  9.2
0) 6,921 (4,925–9,725) 8,129 (5,915–11,171) 4,741 (3,347–6,714)
8) 0.048 (0.037–0.062) 0.074 (0.045–0.121) 0.031 (0.020–0.048)
r-deﬁbrillator; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide.
TABLE 2 Speciﬁc Causes of Death in the RELAX-AHF Study
Cause
Placebo
(n ¼ 580)
Serelaxin
(n ¼ 581)
Total
(N ¼ 1,161)
All causes 65 (11.3) 42 (7.3) 107 (9.3)
Cardiovascular death 54 (9.4) 34 (5.9) 88 (7.7)
HF 17 (3.0) 20 (3.5) 37 (3.3)
Sudden death 17 (3.1) 8 (1.4) 25 (2.3)
Other CV death
Acute coronary syndrome 1 (0.2) 1 (0.2) 2 (0.2)
Complication of cardiac or
vascular procedure
4 (0.7) 0 (0) 4 (0.4)
Stroke 8 (1.4) 1 (0.2) 9 (0.8)
Presumed CV death/unknown 7 (1.3) 4 (0.7) 11 (1.0)
Non-CV death 11 (2.1) 8 (1.5) 19 (1.8)
Pulmonary 2 (0.4) 0 (0) 2 (0.2)
Sepsis 6 (1.1) 3 (0.5) 9 (0.8)
Other infection 0 (0) 2 (0.4) 2 (0.2)
Gastrointestinal 0 (0) 2 (0.4) 2 (0.2)
Hematologic 1 (0.2) 0 (0) 1 (0.1)
Malignancy 2 (0.4) 1 (0.2) 3 (0.3)
Values are n (Kaplan-Meier %).
Abbreviation as in Table 1.
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1595stroke deaths, 3 occurred within the ﬁrst 8 days after
randomization (all 3 in placebo-treated patients), and
the remainder were 35 days or greater from
randomization.
Given the relatively modest total number of
events (107 deaths), we performed formal statistical
testing for heterogeneity as described previously.CENTRAL ILLUSTRATION Treatment Effects of Serelaxin by Mod
Hazard ratios with 95% conﬁdence intervals (CI) are shown for serelaxi
CV ¼ cardiovascular.This analysis could not rule out the possibility
that the variability observed in the effect of
serelaxin on mode of death was due to chance
(p ¼ 0.08), suggesting that results this extreme or
greater for a differential effect on mode of death
would be expected to occur 8% of the time by chance
alone.
TIMING OF DEATHS FROM RANDOMIZATION. The
distribution of deaths over the follow-up period is
shown in Figure 3. Forty-nine of 107 deaths (46%)
occurred within 60 days of randomization, 20 in pa-
tients randomized to serelaxin and 29 in patients
randomized to placebo. In general, early deaths were
much more likely to be CV in nature, with only 1 of
31 (3%) non-CV deaths within 30 days of randomiza-
tion. HF deaths were roughly evenly distributed
across the follow-up time period.
DISCUSSION
Understanding mode of death and timing of events in
patients with HF can provide insight into the mech-
anism of treatment effect of novel therapies. In the
RELAX-AHF study, patients receiving serelaxin
demonstrated a signiﬁcant improvement in both all-
cause and CV mortality at 180 days. The current
analysis suggests that the primary treatment effects
of serelaxin were on other CV events and sudden
death, rather than deaths from HF.e of Death
n versus placebo for each of the 4 categories of mode of death.
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Log-rank p-value = 0.6548
Hazard ratio (95% CI) = 1.158 (0.607, 2.211)6.0
4.0
2.0
0
0
Placebo
Serelaxin
14
580 567 559 547 535 523 514 444
 581 573 563 555 546 542 536 463
580 567 559 547 535 523 514 444
 581 573 563 555 546 542 536 463
580 567 559 547 535 523 514 444
581 573 563 555 546 542 536 463
580 567 559 547 535 523 514 444
 581 573 563 555 546 542 536 463
30 60 90
Time Since Randomization (Days)
HF
/P
um
p 
Fa
ilu
re
 D
ea
th
 (%
)
120 150 180
8.0
Log-rank p-value = 0.0052
Hazard ratio (95% CI) = 0.294 (0.118, 0.733)6.0
4.0
2.0
0
0
Placebo
Serelaxin
14 30 60 90
Time Since Randomization (Days)
Ot
he
r C
ar
di
ov
as
cu
la
r D
ea
th
 (%
)
No
n-
Ca
rd
io
va
sc
ul
ar
 D
ea
th
 (%
)
120 150 180
8.0
Log-rank p-value = 0.0646
Hazard ratio (95% CI) = 0.462 (0.199, 1.070)6.0
4.0
2.0
0
0
Placebo
Serelaxin
14 30 60 90
Time Since Randomization (Days)
Su
dd
en
 D
ea
th
 (%
)
120 150 180
8.0
Log-rank p-value = 0.4554
Hazard ratio (95% CI) = 0.708 (0.285, 1.761)6.0
4.0
2.0
0
0
Placebo
Serelaxin
14 30 60 90
Time Since Randomization (Days)
120 150 180
Placebo
Serelaxin
Placebo
Serelaxin
Placebo
Serelaxin
FIGURE 2 Kaplan-Meier Curves by Speciﬁc Categories of Mode of Death for Serelaxin Versus Placebo
Numbers below the x-axis reﬂect the number of patients at risk. CI ¼ conﬁdence interval; HF ¼ heart failure.
Felker et al. J A C C V O L . 6 4 , N O . 1 5 , 2 0 1 4
Acute HF Mode of Death O C T O B E R 1 4 , 2 0 1 4 : 1 5 9 1 – 8
1596Prior data assessing the impact of other acute
therapies on mode of death are limited, in part
because AHF therapies with a demonstrable effect on
mortality have not previously been identiﬁed. The
most detailed previous data on mode of death in AHF
comes from the EVEREST (Efﬁcacy of Vasopressin
Antagonism in Heart Failure Outcome Study With
Tolvaptan) trial (8). Overall mortality in the EVEREST
trial was signiﬁcantly higher than that observed in
RELAX-AHF (26.1% over a median follow-up of
9.9 months for EVEREST vs. 9.3% at 6 months for
RELAX-AHF). Although the EVEREST trial had a
longer follow-up period than the RELAX-AHF study,
patient characteristics are the most likely explanation
for these differences in outcome. The EVEREST trial
required a history of chronic HF and an ejection
fraction #40% for entry, whereas the RELAX-AHF
trial allowed patients with AHF (including those
with de novo HF) regardless of ejection fraction.
Consistent with these inclusion characteristics, HF
death was substantially more common than sudden
death in the EVEREST trial (which included only
those patients with impaired left ventricular sys-
tolic function), whereas the incidence of HF death
and sudden death were similar in the RELAX-AHFtrial. Additionally, the RELAX-AHF study required
elevated blood pressure (systolic blood pressure
>125 mm Hg) for study entry, whereas the EVEREST
trial only excluded those patients with systolic
blood pressure <90 mm Hg. Higher systolic blood
pressure at presentation was previously demon-
strated to be a favorable prognostic ﬁnding in AHF
and potentially selects patients at lower risk of
dying from HF (14,15).
Many deaths in clinical trials occur outside the
hospital, and details that can provide clues to the
speciﬁc cause of death may be unavailable. The
framework for classifying these “unknown” deaths
may signiﬁcantly inﬂuence the results of mode of
death analyses. These deaths are typically catego-
rized as CV, given the overall burden of CV mortality
in patients with HF. In the current study, we further
subclassiﬁed these unknown deaths into either other
CV or alternatively, in a sensitivity analysis, into
the sudden death category. Our overall results were
not fundamentally changed by the reclassiﬁcation of
these events, with the exception that the treatment
effect of serelaxin on sudden death frequency became
nominally statistically signiﬁcant (p ¼ 0.039) after
reclassiﬁcation.
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FIGURE 3 Mode of Death by Timing From Randomization
Deaths by both mode of death and treatment group over time are shown. Pbo ¼ placebo;
Ser ¼ serelaxin.
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reduction in sudden death frequency with serelaxin
therapy? Multiple putative mechanisms contribute
to sudden death in patients with HF, including
ischemia, myocardial ﬁbrosis, increased sympathetic
tone, neurohormonal activation, electrolyte abnor-
malities, and adverse effects of drug therapies.
In addition to its vasodilatory effects, in experi-
mental models, serelaxin modulates a variety of
relevant biological pathways, including having anti-
inﬂammatory, antiﬁbrotic, and proangiogenic prop-
erties (16). Whether the relatively brief duration of
therapy (48 h) used in the RELAX-AHF study was
sufﬁcient to modulate these pathways to a degree
likely to have downstream effects on the risk of
sudden death is unknown. Serelaxin treatment in the
RELAX-AHF trial was associated with a decreased
pattern of myocardial injury, as reﬂected by tro-
ponin elevations (11). Given the known association
between ischemic injury and subsequent mortality
in HF (16,17), subsequent risk of sudden death could
potentially be affected. Microfoci of ischemia could
potentially predispose patients to ventricular ar-
rhythmias, and prior data from autopsy series sug-
gest that many sudden deaths in patients with HF
are actually related to ACS (18,19). Serelaxin therapy
was also associated with less aggressive use of
diuretics, and diuretic therapy has previously been
linked to the risk of sudden death in chronic HF (20).
Use of ICDs may also impact overall rates of sudden
death—the use of ICDs was relatively low in the
RELAX-AHF study overall (13%), owing, in part, to
the inclusion of patients with preserved ejection
fraction (for whom ICD therapy is generally not
indicated) and to substantial enrollment in Europe,
where ICD usage rates are lower than in North
America. It is, however, notable that 4 of 25 pa-
tients (16%) with deaths classiﬁed as sudden death
had ICDs.
One unexpected ﬁnding of the current analysis
was the marked difference in rate of fatal stroke
between serelaxin and placebo (1 death in the ser-
elaxin group vs. 8 deaths in the placebo group). Prior
data on stroke rates in patients with AHF are sparse.
In the PROTECT (Placebo-Controlled Randomized
Study of the Selective Adenosine A1 Receptor
Antagonist Rolofylline for Patients Hospitalized with
Acute Decompensated Heart Failure and Volume
Overload to Assess Treatment Effect on Congestion
and Renal Function) trial of rolofylline in AHF,
overall stroke rates were approximately 1% at 60
days, and there was a signiﬁcant increase in stroke
associated with randomization to rolofylline (HR:
3.49; p ¼ 0.043) (21). The potential mechanisms ofthe observed decrease in fatal stroke frequency with
serelaxin are speculative, but serelaxin was associ-
ated with controlled decrease in blood pressure over
the 48-h treatment period, which could have
contributed to reduction in stroke risk. However,
only 3 of the stroke events occurred within the ﬁrst
35 days of therapy, and a direct link between short-
term serelaxin treatment and later stroke mortality
appears unlikely. Alternatively, given the low num-
ber of events (9 fatal strokes overall at 180 days),
this ﬁnding could potentially be related to chance
alone.
STUDY LIMITATIONS. Important limitations of this
analysis relate to the number of deaths and associ-
ated statistical power. There were only 107 deaths in
the RELAX-AHF study within 180 days, and many
causes of death, including ACS and stroke, had rela-
tively few events and thus limited statistical power to
make inferences about the impact of serelaxin ther-
apy on speciﬁc modes of death. Thus, there is the
possibility that these ﬁndings were due to chance,
which could not be excluded by formal statistical
testing for heterogeneity of effect. Although central-
ized blinded adjudication of events is considered the
“gold standard” for assessment of endpoints in clin-
ical trials, in many cases, detailed information about
the cause of out-of-hospital death is limited. In an
attempt to minimize the number of deaths classiﬁed
as unknown, our pre-speciﬁed deﬁnition of sudden
death was relatively broad, including patients last
seen alive up to 72 h before death. The RELAX-AHF
study did use standard best practices for clinical
event adjudication, including the use of a blinded
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Intravenous serelaxin improved 6-month mortality
compared with placebo in selected patients with AHF
in the RELAX-AHF study.
COMPETENCY IN PATIENT CARE: Understanding
the effect of speciﬁc treatments on the timing and
mode of death in patients with AHF could inform
medical decision making.
TRANSLATIONAL OUTLOOK: Further studies,
some ongoing, are needed to deﬁne the mechanism
by which serelaxin therapy prolongs survival in
patients with AHF.
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1598endpoint committee of experienced HF physicians as
well as pre-speciﬁed standardized deﬁnitions for
events.
CONCLUSIONS
Treatment of patients with AHF with serelaxin was
associated with signiﬁcant improvements in CV
mortality at 180 days. This effect was primarily driven
by improvements in death frequency from other CV
causes and sudden death, rather than from HF. These
observations will require reassessment in upcoming
larger trials with greater numbers of events.
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